MedTrace Logo

INVAC-1 Anti-Cancer hTERT DNA Immunotherapy

NCT02301754 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-02-26

No results posted yet for this study

Summary

INVAC-1 is intended to be used for the treatment of adult patients with advanced solid tumors unresponsive to currently available therapies, or for whom no standard therapy is available.

Conditions

Interventions

BIOLOGICAL

INVAC-1

intradermal injection combined with electroporation

Sponsors & Collaborators

  • Keyrus Biopharma

    collaborator OTHER

  • Invectys

    lead INDUSTRY

Principal Investigators

  • Stéphane Culine, MD · Hopital St Louis - Paris - France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-02-28
Completion
2018-06-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02301754 on ClinicalTrials.gov